What is HC Wainwright’s Estimate for FULC FY2029 Earnings?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Equities researchers at HC Wainwright issued their FY2029 earnings estimates for shares of Fulcrum Therapeutics in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst A. Fein expects that the company will post earnings per share of ($0.95) for the year. HC Wainwright has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03).

Separately, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $8.63.

Fulcrum Therapeutics Price Performance

Fulcrum Therapeutics stock opened at $3.59 on Thursday. Fulcrum Therapeutics has a fifty-two week low of $2.86 and a fifty-two week high of $13.70. The company’s 50 day simple moving average is $4.11 and its 200 day simple moving average is $4.57. The firm has a market capitalization of $193.78 million, a price-to-earnings ratio of -11.58 and a beta of 2.03.

Institutional Trading of Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in FULC. China Universal Asset Management Co. Ltd. raised its holdings in shares of Fulcrum Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after purchasing an additional 4,701 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Fulcrum Therapeutics in the third quarter valued at approximately $474,000. Intech Investment Management LLC acquired a new stake in shares of Fulcrum Therapeutics in the third quarter valued at approximately $62,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Fulcrum Therapeutics by 223.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock valued at $2,032,000 after purchasing an additional 393,202 shares during the last quarter. Finally, Walleye Capital LLC acquired a new stake in shares of Fulcrum Therapeutics in the third quarter valued at approximately $59,000. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.